TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Objective Response Rate (ORR) at First Assessment by Investigator Review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caudate Signal Intensity in Response to Reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nucleus Accumbens (NAcc) Signal Intensity in Response to Reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Putamen Signal Intensity in Response to Reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum 25-hydroxyvitamin D Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postendodontic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Value of Comfort During the Day
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Overall Quality of Vision at End of Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting That Their Eyes Rarely or Never Felt Dry at End of Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of Adherent Patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportions of Partially Adherent Patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportions of Non-adherent Patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sedation Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: GAIN Substance Problem Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant metastatic control at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose of veliparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of magnetic-controlled capsule endoscopy (MCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status of adult cerebral palsy patients
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental status of adult cerebral palsy patients
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of serum-specific donor antibodies (DSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of Gastroesophageal Reflux (GOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: International Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in neural functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Subjects Who Achieved Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: partial remission at 1 month after the final apheresis treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in burden of atrial fibrillation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Root coverage outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Screening in Serum Albumin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Screening in Urine Calcium/Creatinine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intensity of lower abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Amyloid Load at Month 13 Using Positron Emission Tomography (PET) Technique: Cohort M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Cerebrospinal Fluid (CSF) Concentration of PF-04360365 at 0 Hour on Day 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of tumoral response by DCE-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positron emission tomography (PET) scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Evaluation of Genomic tissular profile in a sample of biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 30% decrease of IOP from baseline after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of individuals with sleep disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Production of Correct Information Units (CIUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 17-hydroxyprogesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Predict response to pre-operative chemoradiation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Leaving Home on Day of Holiday
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inverse Hyperbolic Sine of COVID-19 Cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cognitive decline assessment change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cumulative MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Energy availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum level of fasting apolipoprotein B-48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum level of postprandial apolipoprotein B-48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Treatment Responders in Overall Eyelash Prominence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first recurrence of symptoms of recurrent genital herpes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Insomnia Severity Index (ISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response Rate (PR+CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pO2 in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective disease response at 3 and 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects experiencing greater than or equal to grade 3 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients who experience microbial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects experiencing newly diagnosed or worsening neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with results of dermal filler
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tooth shade changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of response from the index episode of major depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in continuous depression symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Euploid blastulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of unclassifiable sarcomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pCS percentage of reduction ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screw guide wire adjustment times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Screw adjustment times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Deviation of screw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Perforation rate of screw
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Pulmonary Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Renal Flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Six min walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross motor function measure (GMFM) section E
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed up and down stairs test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived postoperative pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Peristomal infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Deaths Within 60 Days of Enrollment
Endpoint domain: Mortality/survival
Primary endpoint: AUCinf of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactivation of latent proviruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Female Sexual function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of violent reinjuries in 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with death in 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Intraprocedural Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Itch VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual evaluation of irradiated skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pittsburgh Sleep Quality Index Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Hba1c mmol/mol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subject Experiencing Remission of MC Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Response for Indications of Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and parasitological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and biological tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Serum Creatinine at 72 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intra-procedural investigational device success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with complete abortion without surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Surgical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in metabolic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time <70 mg/dl by CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anti-Tat Antibody Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection rate of precancerous lesions and cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in inhibitory control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum tolerated dose (MTD) of low dose metronomic (LDM) Topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of LDM Topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum nicotinamide riboside levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell viability of Parathyroid cells after isolation process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell viability of Parathyroid cells after 6 hour of cold ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell viability of Parathyroid cells after 12 hour of cold ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell viability of Parathyroid cells after 18 hour of cold ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell viability of Parathyroid cells after 24 hour of cold ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphatic drainage mapping in the axilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Time required for complete removal of extrinsic stains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With New Chronic Medical Conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Laboratory Measures of Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Normality of estrus cycle after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appearance of erythrocytic parasites (parasitemia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Who Survived Without Disease Progression at 6 Months After Treatment for Glioblastoma Participants With no Prior Bevacizumab Exposure
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Survived Without Disease Progression at 3 Months After Treatment for Glioblastoma Participants With Prior Bevacizumab Exposure
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Survived Without Disease Progression at 6 Months After Treatment for Anaplastic Glioma (AG) Participants With no Prior Bevacizumab Exposure
Endpoint domain: Mortality/survival
Primary endpoint: area under the curve / minimum inhibitory concentration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmin and Cmax of distribution and elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance of distribution and elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Explicit fat bias
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implicit fat bias
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Empathy scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self stigma of mental illness scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery assessment scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-protective Withdrawal and Secrecy scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Ultrasound characteristics of the quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: targeted infections
Endpoint domain: Adverse events/effects
Primary endpoint: 100% granulation of wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of adverse events after intramuscular injection
Endpoint domain: Adverse events/effects
Primary endpoint: prostate cancer knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ability to make an informed decision about prostate cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Decision-making
Primary endpoint: Change in Epworth Sleepiness Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Global Neurocognitive Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acute stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: engagement in needed treatments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: adherence to needed treatments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage volume reduction of lymphoedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Inflammatory Bowel Disease Questionnaire (IBDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Platelet Count Reaching 50 x 10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of primary care face to face visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change of nutritional status after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of quality of life after 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in frequency and severity of local injection site reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of adverse events (AEs) categorized by Medical Dictionary for Regulatory Activities (MedDRA) body system
Endpoint domain: Adverse events/effects
Primary endpoint: Change in distribution of values of safety laboratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional (axillary) recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in Proportion of individuals with Blood Pressure in the controlled range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TMA complication-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Maximal incisal opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Maintain Sinus Rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of energy consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Clearance of Ethambutol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Confirmed Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amphetamine craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of VIZAMYL™ PET Image Interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of VIZAMYL™ PET Image Interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of VIZAMYL™ PET Image Interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of anti-Myelin-oligodendrocyte-glycoprotein (MOG-ab)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensation intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with serum glucose level between 140-180mg/dl during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients who had hyperglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients who had hypoglycemic events
Endpoint domain: Adverse events/effects